Skip to main content

NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.41
▲ +0.31 (5.08%)
1 month | 3 months | 12 months
Get New Merrimack Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MACK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MACK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Merrimack Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.41.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in Merrimack Pharmaceuticals. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2018CowenReiterated RatingHoldMedium
i
Rating by Marc Frahm at Cowen Inc
10/20/2018Robert W. BairdSet Price TargetNeutral ➝ Hold$7.00 ➝ $4.00High
i
Rating by Michael Ulz at Robert W. Baird
10/19/2018CowenReiterated RatingHoldHigh
i
Rating by Marc Frahm at Cowen Inc
6/26/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$12.00 ➝ $7.00High
i
6/25/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
3/15/2018Robert W. BairdReiterated RatingHold$12.00Low
i
10/13/2017Robert W. BairdReiterated RatingHold$15.00N/A
i
5/19/2017CowenReiterated RatingMarket PerformLow
i
1/24/2017CowenReiterated RatingMarket PerformN/A
i
1/12/2017CowenReiterated RatingMarket PerformN/A
i
1/11/2017Robert W. BairdReiterated RatingNeutral$50.00N/A
i
Rating by Michael Ulz at Robert W. Baird
12/23/2016Robert W. BairdReiterated RatingNeutral$70.00N/A
i
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$70.00N/A
i
11/10/2016BTIG ResearchReiterated RatingNeutralN/A
i
Rating by ling wang at BTIG Research
10/7/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$57.50N/A
i
10/5/2016BTIG ResearchReiterated RatingNeutralN/A
i
Rating by ling wang at BTIG Research
9/25/2016BTIG ResearchReiterated RatingNeutralN/A
i
Rating by ling wang at BTIG Research
9/9/2016BTIG ResearchReiterated RatingNeutralN/A
i
Rating by ling wang at BTIG Research
8/19/2016BTIG ResearchInitiated CoverageNeutralN/A
i
8/10/2016Robert W. BairdReiterated RatingNeutral$80.00 ➝ $70.00N/A
i
Rating by Michael Ulz at Robert W. Baird
8/5/2016JPMorgan Chase & Co.Lower Price TargetOverweight$90.00 ➝ $80.00N/A
i
8/5/2016Brean CapitalSet Price TargetBuy$160.00 ➝ $130.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
8/5/2016CowenDowngradeOutperform ➝ Market PerformN/A
i
Rating by Eric Schmidt at Cowen Inc
5/26/2016Robert W. BairdInitiated CoverageNeutral$80.00N/A
i
5/20/2016Brean CapitalReiterated RatingBuy$160.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
5/20/2016MizuhoReiterated RatingBuy$130.00N/A
i
Rating by Eric Criscuolo at Mizuho
(Data available from 5/16/2016 forward)
Merrimack Pharmaceuticals logo
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.41
$6.07
$6.76

50 Day Range

MA: $6.76
$6.04
$7.77

52 Week Range

Now: $6.41
$3.06
$9.45

Volume

49,712 shs

Average Volume

80,027 shs

Market Capitalization

$85.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Merrimack Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Merrimack Pharmaceuticals in the last twelve months:
View the latest analyst ratings for MACK.

What is the current price target for Merrimack Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Merrimack Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Merrimack Pharmaceuticals in the next year.
View the latest price targets for MACK.

What is the current consensus analyst rating for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MACK.

What other companies compete with Merrimack Pharmaceuticals?

How do I contact Merrimack Pharmaceuticals' investor relations team?

Merrimack Pharmaceuticals' physical mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is 617-441-1000 and its investor relations email address is [email protected] The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com.